New Avon hires Helene F. Rutledge as chief innovation officer
Prior to joining New Avon, Ms. Rutledge was the Vice President of Research and Development for Nature’s Bounty, Inc., where she led Product and Partner Development across NBTY's diverse brands and geographies, including solid dose, liquid, powder, food and cosmetic form products.
As an expert on innovation, Ms. Rutledge is currently an invited member of Henry Chesbrough's OI Forum, and previously served as the Head of Global Open Innovation for GlaxoSmithKline Consumer Healthcare and Senior Vice President of Technology at AeroDesigns.
During her time at AeroDesigns, Ms. Rutledge collaborated with David Edwards, inventor of inhaled insulin, at his incubator Le Laboratoire in Paris.
She also held operations and product development roles with Pfizer, GoSMILE and Warner-Lambert where she led development of innovation award-winning Listerine(R) PocketPaks.
Additionally, she is the founder of the full-service NYC-based consultancy firm Caliper Innovation, which designs, develops and delivers products and innovation solutions.
Earlier in her career, Ms. Rutledge worked at Avon Products, Inc., leading process development for Fragrance, Children's and Bath products. ■
LATEST MOVES FROM New York
- American Express appoints Stephen J. Squeri as CEO and chairman
- AzurRx BioPharma appoints Vern Lee Schramm to board
- Nature's Bounty appoints Mark Gelbert as CSO
- Global Net Lease appoints Christopher J. Masterson as CFO
- Bristol-Myers Squibb appoints Saurabh Saha as SVP
More inside POST